Study Shows Predisposed Cancer Factors in Ashkenazi Jewish Women
By LabMedica International staff writers Posted on 07 Aug 2017 |
Image: A new study suggests that Ashkenazi Jewish women can benefit from genetic testing for all known breast cancer genes (Photo courtesy of the University of Washington).
Upon finding additional breast cancer mutations in Ashkenazi Jewish breast cancer patients, a new study suggests that this population of women can benefit from genetic testing for all known breast cancer genes.
There are 3 known founder-mutations in BRCA1 and BRCA2 (BRAC1/2) that severely increase the risk of breast and ovarian cancer in Ashkenazi Jewish women. In the new study, led by Mary-Claire King, PhD, of the University of Washington (Seattle, WA, USA), researchers looked for other BC-predisposing mutations in this population. They performed multiplex genomic sequencing, for all known and candidate breast cancer genes, on DNA from 1,007 women of Ashkenazi Jewish ancestry with breast cancer. Of these 1,007 patients, 903 had none of the 3 BRCA1/2 founder mutations. Of those 903 patients, seven (0.8%) carried a different mutation in BRCA1 or BRCA2 and 31 (3.4%) carried a damaging mutation in another breast cancer gene.
The study notes two limitations, including that they only sequenced genes that were known or suspected to harbor mutations that increase the risk of breast cancer.
The study, by Walsh T et al, was published July 20, 2017, by the journal JAMA Oncology.
Related Links:
University of Washington
There are 3 known founder-mutations in BRCA1 and BRCA2 (BRAC1/2) that severely increase the risk of breast and ovarian cancer in Ashkenazi Jewish women. In the new study, led by Mary-Claire King, PhD, of the University of Washington (Seattle, WA, USA), researchers looked for other BC-predisposing mutations in this population. They performed multiplex genomic sequencing, for all known and candidate breast cancer genes, on DNA from 1,007 women of Ashkenazi Jewish ancestry with breast cancer. Of these 1,007 patients, 903 had none of the 3 BRCA1/2 founder mutations. Of those 903 patients, seven (0.8%) carried a different mutation in BRCA1 or BRCA2 and 31 (3.4%) carried a damaging mutation in another breast cancer gene.
The study notes two limitations, including that they only sequenced genes that were known or suspected to harbor mutations that increase the risk of breast cancer.
The study, by Walsh T et al, was published July 20, 2017, by the journal JAMA Oncology.
Related Links:
University of Washington
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans